Case Studies in Clinical Decision Making in mCRC

Access Course


The use and challenges of immunotherapy in patients with MSI-H CRC is explored through 2 cases.


This activity is intended for oncologists, gastroenterologists, surgeons, nurses, pharmacists, and other healthcare professionals who treat patients with colorectal cancer (CRC).


The goal of this activity is to examine the management of microsatellite instability-high (MSI-H) CRC, including testing and treatment with immunotherapy.


Approximate Time to Complete: 30 minutes


Credit Available: Dec. 18, 2018 - Dec. 18, 2019


Developed through a partnership between SITC and Medscape.

sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
Course Objectives
Upon completion of this activity, participants will be able to:
  • Have increased knowledge regarding the ongoing trials of immune checkpoint inhibitors (ICIs) alone or in combination for the management of metastatic colorectal cancer (mCRC)
  • Have greater competence related to selecting the most appropriate regimen for patients with MSI-H mCRC
  • Have increased knowledge regarding the Importance of testing for microsatellite instability (MSI)
  • Have greater competence related to Managing immune-related adverse events (irAEs) in a patient with mCRC
  • Have greater competence related to communication among the interprofessional care team so as to ensure optimal coordination of care in patients with MSI-H mCRC
Accreditation Council for Continuing Medical Education (MD/DO)
AMA PRA Category 1 Credit(s)™: 1.00
American Board of Internal Medicine
ABIM MOC Part 2 Credits: 1.00
Accreditation Council for Pharmacy Education
CEU: 1.00
(0.100 CEUs)
American Nurses Credentialing Center's Commission on Accreditation
Contact Hour: 1.00
(1 contact hours are in the area of pharmacology)